The features of optimal nonhormonal therapy of vegetative disorders among women with postmenopause

Abstract

Objectives: to evaluate the clinical effectiveness of the Vitae-Melatonin in the complex treatment of vegetative disorders in postmenopausal women.Materials and methods. The 64 postmenopausal women who complained of vegetative disorders were included in our prospective study. Patients were divided into clinical groups. The first group consisted of 31 women who were prescribed a herbal preparation of Cimicifuga racemosa extract – 30 mg/day for 3 months. The second group included 33 patients who received in addition to the herbal medicine Vitae-Melatonin 3 mg/day every evening 2 hours before bedtime for 1 month. The clinical effectiveness of the therapy was assessed 1, 2 and 3 months after the start of treatment based on the dynamics of psychological disorders, somatic symptoms, vasomotor and sexual disorders, sleep problems and satisfaction with the therapy.Results. The use of herbal medicine containing Cimicifuga rhizome extract alone or in combination with Vitae-Melatonin in postmenopausal women significantly reduced the manifestations of vegetative disorders, including psychological and dyssomnia in a month from the start of therapy. After 3 months from the start of therapy, the advantage of combined therapy involving Vitae-Melatonin compared to the monotherapy of Cimicifuga rhizome was marked by a significant reduction of psychological disorders, somatic symptoms, vasomotor disorders and sleep problems (р = 0.003, р = 0.01, р = 0.02 and p = 0.015, respectively). Patient satisfaction with the combined therapy of vegetative disorders during the menopause compared to monophytotherapy was probably higher (risk ratio 1.63, 95% confidence interval 1.09–2.44, p = 0.018). There was no significant difference between the two research groups regarding side effects during and after the use of the drugs (p > 0.05).Conclusions. The use of Vitae-Melatonin at a dose of 3 mg/day in addition to phytotherapy in postmenopausal women had a clear clinical effect, which was a significant reduction of vegetative disorders, both compared to the initial indicators and in comparison with monophytotherapy. Results of the study showed the safety of melatonin, as well as the willingness of participants to continue using melatonin after 3 months of the treatment.